Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS is vulnerable to reversible switch-II pocket engagement in cells
James D. Vasta, D. Matthew Peacock, Qinheng Zheng, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 6, pp. 596-604
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 300
Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile
Ziyang Zhang, Johannes Morstein, Andrew K Ecker, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 35, pp. 15916-15921
Open Access | Times Cited: 91
Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation
Fabienne Müller, Jonathan K.M. Lim, Christina M. Bebber, et al.
Cell Death and Differentiation (2022) Vol. 30, Iss. 2, pp. 442-456
Open Access | Times Cited: 79
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Qinheng Zheng, Ziyang Zhang, Keelan Z. Guiley, et al.
Nature Chemical Biology (2024) Vol. 20, Iss. 9, pp. 1114-1122
Open Access | Times Cited: 32
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Simon Manuel Tria, Matthew Burge, Vicki Whitehall
Cancers (2023) Vol. 15, Iss. 8, pp. 2375-2375
Open Access | Times Cited: 20
Eliminating oncogenic RAS: back to the future at the drawing board
Candy Laura Steffen, Pelin Kaya, Elisabeth Schaffner‐Reckinger, et al.
Biochemical Society Transactions (2023) Vol. 51, Iss. 1, pp. 447-456
Open Access | Times Cited: 19
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
Xiaohua Duan, Tuo Zhang, Lingling Feng, et al.
Cell stem cell (2023) Vol. 31, Iss. 1, pp. 71-88.e8
Closed Access | Times Cited: 17
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Targeting KRAS in PDAC: A New Way to Cure It?
Qianyu He, Zuojia Liu, Jin Wang
Cancers (2022) Vol. 14, Iss. 20, pp. 4982-4982
Open Access | Times Cited: 26
Direct Modulators of K-Ras–Membrane Interactions
Johannes Morstein, Rebika Shrestha, Que N. Van, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 9, pp. 2082-2093
Open Access | Times Cited: 15
Monophthalates of betulinic acid and related pentacyclic triterpenes inhibit efficiently the SOS-mediated nucleotide exchange and impact PI3K/AKT signaling in oncogenic K-RAS4B proteins
Gerrit E. Benary, Frank Kilgenstein, Sascha Koller, et al.
RSC Advances (2025) Vol. 15, Iss. 2, pp. 883-895
Open Access
Chaperone Directed Heterobifunctional Molecules Circumvent Krasg12c Inhibitor Resistance
Takeshi Shimamura, Inés Pulido, Qiyue Luan, et al.
(2025)
Closed Access
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways
Hnin Ei Ei Khine, Utid Suriya, Thanyada Rungrotmongkol, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.
Inés Pulido, Qiyue Luan, Sara Pastor-Puente, et al.
Cancer Letters (2025), pp. 217691-217691
Open Access
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma
Huan He, Yu Zhang, Juan Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 13158-13171
Closed Access | Times Cited: 19
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance
Ruth Nussinov, Hyunbum Jang
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 231-253
Closed Access | Times Cited: 12
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
Katharine M. Wright, Sarah R. DiNapoli, Michelle S. Miller, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer
Claudio Fukumori, Paola Cristina Branco, Thayná Lopes Barreto, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 187, pp. 106465-106465
Open Access | Times Cited: 11
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Yi Chen, Qiu-pei Liu, Hua Xie, et al.
Acta Pharmacologica Sinica (2023) Vol. 45, Iss. 4, pp. 686-703
Closed Access | Times Cited: 11
Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket
Lauren Wallon, Imran Khan, Kai Wen Teng, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 43
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top